CrossRef Anti-diabetic Drugs and Cancer: Integrated Mechanisms of Tumor Suppression and Clinical Translation Mahya Asadalizadeh, Mohammad Kazem Molavi Rahbar, Tabassom Mahmoudie, Mahshid Abbasi, Mitra Akbari, Davoud Shakiba, Aida Mohammadiun Shabestari, Meysam Ebrahimifar Indian Journal of Clinical Biochemistry.2026;[Epub] CrossRef Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis Gaetano Lauri, Paolo Giorgio Arcidiacono, Antonio Facciorusso, Gabriele Capurso, Matteo Tacelli Pancreatology.2026;[Epub] CrossRef GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns Klaudia Nowak, Krzysztof upina, Aleksandra Kalisz, ucja Ilkiewicz, Jakub Janczura Current Pharmacology Reports.2026;[Epub] CrossRef Optimizing glycemic control in oncology patients with diabetes mellitus S
He had a little sister
The market is growing primarily due to new drug launches
Thats why fad diets or extreme restriction often backfire
Walk into this comparison expecting a simple answer and youll leave with a more useful one
2 Data search An extensive search was done on published reports from specialized data sources, including PubMed/MedLine, ScienceDirect, Google Scholar, SciFinder, Scopus, and the TRIP Database